Navigation Links
Microbix Signs Marketing Agreement For Kinlytic(R)(Urokinase) In Growing Middle East Region
Date:11/17/2009

Riso Pharma guarantees to purchase 50,000 KINLYTIC vials over next three years

TORONTO, Nov. 17 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (MBX:TSX), a biotech company focused on virology and biological technologies, today announced a marketing and supply agreement with Riso Pharma that guarantees purchases of not less than 50,000 KINLYTIC vials over the next three years. KINLYTIC (Urokinase) is Microbix' thrombolytic agent for treating pulmonary embolism.

Under the terms of the agreement, Microbix will grant Riso exclusive rights to market KINLYTIC throughout the Middle East. Microbix will share in the revenues from KINLYTIC sales in all countries covered by the agreement and Riso will be responsible for all commercialization activities. Microbix expects KINLYTIC sales to commence around mid-year 2010.

Mark A. Cochran, Microbix' Chief Business Officer, said, "Microbix is off to a great start as we bring KINLYTIC back to the world's medical community. We expect to provide our clot-busting therapy to other parts of the world by signing additional agreements, such as this one, throughout 2010. And, while final pricing for our therapy has not been yet established, even at a discounted pricing offered to these emerging markets, Microbix will profit substantially from this agreement covering the Middle East."

The market for pharmaceutical sales in the Middle East is valued today at $12 billion and is expected to grow 10 to 15 percent annually, according to published pharmaceutical market reports. Growth in this region is being forecast for the pharmaceutical and biotechnology industries due to moves by Middle Eastern nations to liberalize national economies and introduce universal health care coverage.

P. Daniel Bagi, M.D., Managing Director of Riso Pharma, said, "We are very pleased to add KINLYTIC to our diverse product offerings throughout the Middle East. As with all of our product sales, we
'/>"/>

SOURCE Microbix Biosystems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Microbix Biosystems Re-files Annual Results With OSC
2. Microbix Biosystems Provides a Corporate Update
3. Microbix And Hunan Biopharmaceutical To Build Asias Largest Influenza Vaccine Facility
4. Microbix Sales Grow 22% For Nine Months
5. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
6. Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half 09
7. Microbix Announces A New Technology Platform For The SST Project
8. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
9. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
10. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
11. DATATRAK Signs New Client for Rescue Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... disease, today announced the next step in its expanded ... solutions provider with the naming of current Chief Operating ... Executive Officer, while current Chairman of the Board and ... as Chairman. These changes are effective January 1, 2015. ...
(Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
(Date:12/17/2014)... , Dec. 17, 2014   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, announced today its ... held in San Francisco, CA. ... Chief Executive Officer, will present on Monday, January 12, ... presentation will be webcast live and may be accessed ...
(Date:12/15/2014)... NEW YORK & PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI ), a leading ... announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. ... Israel,s Office of the Chief ... has been in receipt of grant support from the ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... Experts ... Life Sciences industry , ... Wayne, PA (PRWEB) February 2, 2010 -- MODA Technology Partners, a global ... industry, today announced four new members to its product advisory board focused on improving ...
... EXTON, Pa. , Feb. 2 ... company focused on the development of regenerative cell therapy ... David Pernock , Chairman of the Board of ... immediately. Pernock most recently served as Senior Vice President ...
... , SANTA ROSA, Calif. , ... EcoNugenics introduces the newest in their scientifically ... Rosa, CA -based nutraceutical company, founded in 1995 by integrative medicine pioneer, ... has once again demonstrated excellence in being at the forefront of the ...
Cached Biology Technology:MODA Names New Members to QC Micro Advisory Board 2Fibrocell Science, Inc. Names David Pernock Chief Executive Officer 2Fibrocell Science, Inc. Names David Pernock Chief Executive Officer 3Just in Time for Heart Health Month... TRIPLE Cardiovascular Health Support From EcoNugenics 2Just in Time for Heart Health Month... TRIPLE Cardiovascular Health Support From EcoNugenics 3
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the leading ... study that pinpoints fine-scale differences in genetic ancestry of ... . Since immigrants first arrived more than ... has served as a meeting place for ... history and the ongoing mixing of peoples with African, ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... can sustain increasing world-wide demand for at least a ... most important restrictions on future copper production. Researchers ... robust compilation and analysis of worldwide copper resources to ... important metal would run out in around 30 years, ...
... potential new antibiotic which could help in the battle ... antibiotic targets a bacterial enzyme critical to metabolic processes. ... to the enzyme (called biotin protein ligase), stopping its ... "Existing antibiotics target the bacterial cell membranes but ...
... bacteria that form the base of the ocean,s food ... new study. In climate change, as in everything, ... levels and temperature rise globally, scientists increasingly want to ... in the environment of tomorrow. The answer to ...
Cached Biology News:After millennia of mining, copper nowhere near 'peak' 2Novel chemistry for new class of antibiotic 2Greenhouse gas likely altering ocean foodchain 2